SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc. (Amendment)
$SNDX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2025 | $40.00 | Buy | H.C. Wainwright |
| 9/10/2025 | $44.00 | Buy | Stifel |
| 9/4/2025 | $34.00 | Buy | Guggenheim |
| 8/5/2025 | $43.00 → $56.00 | Buy | BTIG Research |
| 7/10/2025 | $18.00 | Buy | Goldman |
| 10/24/2024 | $37.00 | Buy | UBS |
| 6/28/2024 | $37.00 | Buy | Jefferies |
| 1/31/2024 | $36.00 → $23.00 | Sector Outperform → Sector Perform | Scotiabank |
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF – – SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas – – Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 – – R&D Event featuring three thought leaders and members of Syndax’s leadership team to be held today at 8:30 a.m. ET
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About S
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29) MRD negativity among CRc responders – – Post-hoc analysis of patients with R/R NPM1m, KMT2Ar, or NUP98r acute leukemia in the AUGMENT-101 trial who resumed revumenib post-HSCT shows an observed 1-year OS of 95% – – Phase 1 trial and expanded access experience shows 28% (7/25) ORR in R/R NUP98r acute leukemia, a subtype with a poor prognosis and high unmet need – – Ph 2 SAVE trial of revumenib w
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
H.C. Wainwright resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $40.00
Stifel resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $44.00
Guggenheim resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $34.00
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF – – SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas – – Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 – – R&D Event featuring three thought leaders and members of Syndax’s leadership team to be held today at 8:30 a.m. ET
– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26, resulting in Syndax collaboration revenue of $15.9 million – – New revumenib real-world, frontline, and post-HSCT maintenance data anticipated in 2Q26 – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Confere